Department of Health and Human Services, through National Institutes of Health, awarded March Biosciences Inc of Houston, TX $2,249,214 under the SBIR program (Phase II), with work starting 2025-07-01 and running to 2027-06-30. It is one of 2 SBIR and STTR awards March Biosciences Inc received in the last two years, $2,648,217 in all. Each figure links to the federal record.
The award
| Recipient | March Biosciences Inc (Houston, TX) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $2,249,214 |
| Period of performance starts | 2025-07-01 |
| Period of performance ends | 2027-06-30 |
| Award number | R44CA302357 (grant, CFDA 93.395) |
| Assistance listing | 93.395, Cancer Treatment Research |
| Place of performance | Houston, Harris County, TX |
| Signed | 2025-06-20 |
| Recipient registry id (UEI) | TB1TRLB85UY7 |
Want the whole picture on March Biosciences Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on March Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on March Biosciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
A phase 2 multi-center trial of CD5 car t-cell therapy in patients with t-cell lymphoma - abstract relapsed and refractory t-cell lymphoma (r/r tcl) represents a significant clinical challenge, with limited therapeutic o
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-31 | Continuation | 001 | $1,124,607 |
| 2026-07-30 | Revision | 000 | $0 |
| 2025-06-20 | New | 000 | $1,124,607 |
A phase 2 multi-center trial of CD5 car t-cell therapy in patients with t-cell lymphoma - abstract relapsed and refractory t-cell lymphoma (r/r tcl) represents a significant clinical challenge, with limited therapeutic options and a 3-YEAR survival rate of less than 20%. Although chimeric antigen receptor (car) t-cell therapies have demonstrated success in treating b-cell malignancies, their application to t-cell cancers is limited by the shared expression of targetable antigens between healthy and malignant t-cells, leading to car t-cell fratricide and increased risk of severe immunodeficiency. CD5 is a key surface marker expressed in 85% of tcl. The innovative CD5 car t-cell therapy (MB-105) developed at baylor college of medicine (bcm) and licensed to march biosciences, has addressed the unique challenges of treating t-cell malignancies. Unlike conventional car-t strategies, MB-105 is engineered to resist fratricide, allowing selective targeting and eradication of malignant t-cells while preserving normal t-cells. The MB-105 manufacturing process has been optimized throughout the phase 1 study to boost car t-cell fitness and improve clinical activity. This approach has demonstrated safety and promising efficacy in a phase 1 trial conducted at bcm. Under the original manufacturing process, MB-105 was well tolerated at all dose levels and demonstrated robust anti-tumor activit ...
From the federal award record.
Other SBIR and STTR awards to March Biosciences Inc
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-22 | Department of Health and Human Services | SBIR Phase I | $399,003 | Overcoming immune evasion in hepatocellular carcinoma with engineered t-cell therapy - abs (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on March Biosciences IncLook up March Biosciences Inc and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.